Cassava Sciences, Inc. (SAVA)
Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company is engaged in discovering and developing small molecule drugs aimed at addressing underlying causes of neurodegeneration and cognitive decline. Cassava Sciences is also involved in research to better understand the pathology of Alzheimer’s and to identify potential biomarkers for diagnosis and treatment efficacy.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 24, 2012 | $0.75 | 2012-12-13 | 2012-12-17 |
| December 10, 2010 | $2.00 | 2010-12-13 | 2010-12-01 |
Dividends Summary
- Cassava Sciences, Inc. has issued 2 dividend payments over the past 2 years
- The most recent dividend was paid 4685 days ago, on December 24, 2012
- The highest dividend payed out to investors during this period was $2.00 per share
- The average dividend paid during this period was $1.38 per share.
Company News
LEQEMBI, an Alzheimer's disease treatment developed by Biogen and Eisai, has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. The Alzheimer's disease market is highly competitive, with numerous companies advancing therapies in the pipeline.
Cassava Sciences, a clinical-stage biotech company, has agreed to pay $40 million to settle charges brought by the SEC related to negligence-based disclosures about a clinical trial for its Alzheimer's drug simufilam. The settlement will significantly impact the company's finances, but it allows them to focus on completing the ongoing phase 3 tri...
Crude oil prices rose 2%, while shares of Five Below plunged 21% after the company announced a CEO transition and a decrease in comparable sales.
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Science reports that an investigation accuses neuroscientist who often worked with Cassava of 'scientific misconduct' across multiple papers.